The safety and efficacy of solifenacin as compared to mirabegron in overactive bladder syndrome patients in the adult population of dera ismail khan

An overactive bladder syndrome is a group of symptoms, i.e., frequency, urgency, nocturia, and sometimes accompanied by urge incontinence. The recent pharmacological options are some drugs, mainly used anti-muscarinic. However, anti-muscarinic drugs have different adverse effects, i.e., constipation and dry mouth. In 2011, a β3 receptor agonist, mirabegron, was studied to treat overactive bladder syndrome. This non-randomized trial was conducted in the Department of Urology, Gomal medical college, D.I. Khan, KPK Pakistan. The study was done from June 2018 to January 2022. We divided 4220 patients into two equal groups. Group a used solifenacin 5 mg for 6 weeks, while group B used mirabegron 50 mg for the same duration. We assessed safety and efficacy after 6 weeks. Most of the adverse effects were mild to moderate severity. Dry mouth occurred in 125 patients out of 2110 (5.92%) in group A and 66 out of 2110 (3.12%) in group B. p-value = 0.0001. Constipation occurred in 53 (2.51%) patients in group A and 46 (2.18%) patients in group B. p-value=0.5417. The improvement in overactive bladder symptoms score (OBSS) occurred in 1443 out of 2110 (68.38%) patients in group A and 1409 out of 2110 (66.77%) patients in group B. p-value=0.2778. Based on the results, it can be concluded that Mirabegron has fewer adverse effects than solifenacin, while both drugs are approximately similar in efficacy.